179 related articles for article (PubMed ID: 37645415)
1. The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL.
Sun J; Yan L
Front Endocrinol (Lausanne); 2023; 14():1188944. PubMed ID: 37645415
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Efficiency of Pan-Immune-Inflammation Value to Predict Prostate Cancer in Patients with Prostate-Specific Antigen between 4 and 20 ng/mL.
Zhu M; Zhou Y; Liu Z; Jiang Z; Qi W; Chen S; Wang W; Shi B; Zhu Y
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769469
[TBL] [Abstract][Full Text] [Related]
3.
Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
5. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
[No Abstract] [Full Text] [Related]
6. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of the diagnostic accuracy across prostate health index, prostate health index density, and percentage free prostate-specific antigen for clinically significant prostate cancer: a prospective diagnostic study.
Wu B; Shao Y; Lin X; Hasi C; Jia W; Wang D; Cao X
Transl Androl Urol; 2023 Mar; 12(3):425-432. PubMed ID: 37032752
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
[TBL] [Abstract][Full Text] [Related]
9. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
10. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
11. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
12. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
13. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
14. Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection.
Chiu ST; Cheng YT; Pu YS; Lu YC; Hong JH; Chung SD; Chiang CH; Huang CY
Front Oncol; 2021; 11():772182. PubMed ID: 34869007
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.
Sun J; Tian T; Wang N; Jing X; Qiu L; Cui H; Liu Z; Liu J; Yan L; Li D
Front Endocrinol (Lausanne); 2024; 15():1338420. PubMed ID: 38384968
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer].
Sun KX; Yan CL; Li ZY; Liu P; Zhang W; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):234-239. PubMed ID: 32306004
[TBL] [Abstract][Full Text] [Related]
20. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Stephan C; Vincendeau S; Houlgatte A; Cammann H; Jung K; Semjonow A
Clin Chem; 2013 Jan; 59(1):306-14. PubMed ID: 23213080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
